Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

European Respiratory Journal - Tập 55 Số 5 - Trang 2000547 - 2020
Guan Wei1,2, Wenhua Liang3,2, Yi Zhao3,2, Heng-rui Liang3,2, Zi‐Sheng Chen3,4,2, Yi Min Li5, Xiaoqing Liu5, Ru-chong Chen1, Chun-li Tang1, Tao Wang1, Chun‐Quan Ou6, Li Li6, Ping Yan Chen6, Ling Sang5, Wei Wang3, Jian-fu Li3, Caichen Li3, Li-min Ou3, Bo Cheng3, Shan Xiong3, Zheng-yi Ni7, Jie Xiang7, Yu Hu8, Lei Liu9,10, Hong Shan11, Chun-liang Lei12, Yi-xiang Peng13, Li Wei14, Yong Liu15, Ya Hu16, Peng Peng17, Jian Ming Wang18, Jiyang Liu19, Zhong Chen20, Gang Li21, Zhi Zheng22, Shao-qin Qiu23, Jie Luo24, Chang-jiang Ye25, Shao Zhu26, Lin-ling Cheng1, Feng Ye1, Shi-yue Li1, Jintao Zheng1, Nuo-fu Zhang1, Nan-shan Zhong1, Jian-xing He3
1State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China
2These authors are joint first authors
3Dept of Thoracic Oncology and Surgery, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
4The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China
5Dept of Pulmonary and Critical Care Medicine, China State Key Laboratory of Respiratory Disease and National Clinical Research Center for Respiratory Disease, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
6State Key Laboratory of Organ Failure Research, Dept of Biostatistics, Guangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China
7Wuhan Jin-yintan Hospital, Wuhan, China
8Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9Shenzhen Third People’s Hospital, Shenzhen, China
10The Second Affiliated Hospital of Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, China
11The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China
12Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou, China
13The Central Hospital of Wuhan, Wuhan, China
14Wuhan No. 1 Hospital, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China
15Chengdu Public Health Clinical Medical Center, Chengdu, China
16Huangshi Central Hospital of Edong Healthcare Group, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China
17Wuhan Pulmonary Hospital, Wuhan, China
18Tianyou Hospital Affiliated to Wuhan University of Science and Technology, Wuhan, China
19The First Hospital of Changsha, Changsha, China
20The Third People's Hospital of Hainan Province, Sanya, China
21Huanggang Central Hospital, Huanggang, China
22Wenling First People's Hospital, Wenling, China
23The Third People's Hospital of Yichang, Yichang, China
24Affiliated Taihe Hospital of Hubei University of Medicine, Shiyan, China
25Xiantao First People's Hospital, Xiantao, China
26The People’s Hospital of Huangpi District, Wuhan, China

Tóm tắt

Background

The coronavirus disease 2019 (COVID-19) outbreak is evolving rapidly worldwide.

Objective

To evaluate the risk of serious adverse outcomes in patients with COVID-19 by stratifying the comorbidity status.

Methods

We analysed data from 1590 laboratory confirmed hospitalised patients from 575 hospitals in 31 provinces/autonomous regions/provincial municipalities across mainland China between 11 December 2019 and 31 January 2020. We analysed the composite end-points, which consisted of admission to an intensive care unit, invasive ventilation or death. The risk of reaching the composite end-points was compared according to the presence and number of comorbidities.

Results

The mean age was 48.9 years and 686 (42.7%) patients were female. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached the composite end-points. 399 (25.1%) reported having at least one comorbidity. The most prevalent comorbidity was hypertension (16.9%), followed by diabetes (8.2%). 130 (8.2%) patients reported having two or more comorbidities. After adjusting for age and smoking status, COPD (HR (95% CI) 2.681 (1.424–5.048)), diabetes (1.59 (1.03–2.45)), hypertension (1.58 (1.07–2.32)) and malignancy (3.50 (1.60–7.64)) were risk factors of reaching the composite end-points. The hazard ratio (95% CI) was 1.79 (1.16–2.77) among patients with at least one comorbidity and 2.59 (1.61–4.17) among patients with two or more comorbidities.

Conclusion

Among laboratory confirmed cases of COVID-19, patients with any comorbidity yielded poorer clinical outcomes than those without. A greater number of comorbidities also correlated with poorer clinical outcomes.

Từ khóa


Tài liệu tham khảo

World Health Organization. www.who.int Date last accessed: 10 March 2020.

World Health Organization. Coronavirus disease (COVID-19) situation reports. www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/ Date last accessed: 10 March 2020.

10.1016/S0140-6736(20)30183-5

10.1016/S0140-6736(20)30211-7

Wang D , Hu B , Hu C , et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020; in press [https://doi.org/10.1001/jama.2020.1585]. doi:10.1001/jama.2020.1585

Kui L , Fang YY , Deng Y , et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J 2020; in press [https://doi.org/10.1097/CM9.0000000000000744]. doi:10.1097/CM9.0000000000000744

10.1136/bmj.m606

10.1016/S0140-6736(20)30154-9

Zhang S , Li H , Huang S , et al. High-resolution CT features of 17 cases of coronavirus disease 2019 in Sichuan province, China. Eur Respir J 2020; in press [https://doi.org/10.1183/13993003.00334-2020]. doi:10.1183/13993003.00334-2020

Wang L , Gao YH , Iou L , et al. The clinical dynamics of 18 cases of COVID-19 outside of Wuhan, China. Eur Respir J 2020; in press [https://doi.org/10.1183/13993003.00398-2020]. doi:10.1183/13993003.00398-2020

Yao Y , Tian Y , Zhou J , et al. Epidemiological characteristics of SARS-CoV-2 infections in Shaanxi, China by 8 February 2020. Eur Respir J 2020; in press [https://doi.org/10.1183/13993003.00310-2020]. doi:10.1183/13993003.00310-2020

Guan WJ , Ni ZY , Hu Y , et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; in press [https://doi.org/10.1056/NEJMoa2002032]. doi:10.1056/NEJMoa2002032

10.1056/NEJMoa1305584

Placzek, 2014, Association of age and comorbidity on 2009 influenza A pandemic H1N1-related intensive care unit stay in Massachusetts, Am J Public Health, 104, e118, 10.2105/AJPH.2014.302197

Mauskopf, 2013, The burden of influenza complications in different high-risk groups, J Med Economics, 16, 264, 10.3111/13696998.2012.752376

10.1086/653204

Martinez, 2019, Risk factors associated with severe outcomes in adult hospitalized patients according to influenza type and subtype, PLoS One, 14, e0210353, 10.1371/journal.pone.0210353

Gutiérrez-González, 2019, Effect of vaccination, comorbidities and age on mortality and severe disease associated with influenza during the season 2016–2017 in a Spanish tertiary hospital, J Infect Public Health, 12, 486, 10.1016/j.jiph.2018.11.011

10.1001/jama.289.21.JOC30885

Alqahtani, 2018, Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study, Epidemiol Infect, 5, 1

Badawi, 2016, Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV), Int J Infect Dis, 49, 129, 10.1016/j.ijid.2016.06.015

Rahman, 2019, Risk factors for fatal Middle East Respiratory Syndrome coronavirus infections in Saudi Arabia: analysis of the WHO line list, 2013–2018, Am J Public Health, 109, 1288, 10.2105/AJPH.2019.305186

Alanazi, 2020, Diabetes mellitus, hypertension, and death among 32 patients with MERS-CoV infection, Saudi Arabia, Emerg Infect Dis, 26, 166, 10.3201/eid2601.190952

Yang, 2017, Impact of comorbidity on fatality rate of patients with Middle East Respiratory Syndrome, Sci Rep, 7, 11307, 10.1038/s41598-017-10402-1

Garbati, 2016, A comparative study of clinical presentation and risk factors for adverse outcome in patients hospitalised with acute respiratory disease due to MERS coronavirus or other causes, PLoS One, 11, e0165978, 10.1371/journal.pone.0165978

10.1093/aje/kww013

Kulscar, 2019, Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection, JCI Insight, 20, e131774

10.1186/s12889-016-3881-4

World Health Organization. Clinical management of severe acute respiratory infection when COVID-19 is suspected. www.who.int/internal-publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected Date last updated: 13 March 2020; date last accessed: 10 March 2020.

10.1164/rccm.201908-1581ST

10.1016/j.ijid.2015.07.026

Gearhart, 2019, Predicting the need for ICU admission in community-acquired pneumonia, Respir Med, 155, 61, 10.1016/j.rmed.2019.07.007

Fang, 2018, Chronic obstructive pulmonary disease in China: a nationwide prevalence study, Lancet Respir Med, 6, 421, 10.1016/S2213-2600(18)30103-6

10.1186/1471-2105-15-333

Naqvi, 2017, Developing an integrated treatment pathway for a post-coronary artery bypass grating (CABG) geriatric patient with comorbid hypertension and type 1 diabetes mellitus for treating acute hypoglycemia and electrolyte imbalance, J Pharm Bioallied Sci, 9, 216, 10.4103/jpbs.JPBS_33_17

Murphy, 2017, Contributions of COPD, asthma, and ten comorbid conditions to health care utilization and patient-centered outcomes among US adults with obstructive airway disease, Int J Chron Obstruct Pulmon Dis, 12, 2515, 10.2147/COPD.S139948

Thông tin
Thông tin xuất bản

European Respiratory Journal

Tập 55 Số 5

2000547

Thông tin tác giả